Title:
USE OF COMBINATION OF ANTI-PD-1 ANTIBODY AND ANTI-VEGF ANTIBODY IN TREATMENT OF HEPATOCELLULAR CARCINOMA
Document Type and Number:
WIPO Patent Application WO/2023/134787
Kind Code:
A3
Abstract:
The present invention provides a pharmaceutical combination of an anti-PD-1 antibody or an antigen binding fragment thereof and an anti-VEGF antibody or an antigen binding fragment thereof, and a use of a pharmaceutical combination in preparation of a drug for treating hepatocellular carcinoma. The anti-PD-1 antibody or the antigen binding fragment thereof comprises amino acid sequences LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, and amino acid sequences HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6.
Inventors:
YAO SHENG (CN)
FENG HUI (CN)
FENG HUI (CN)
Application Number:
PCT/CN2023/081308
Publication Date:
September 07, 2023
Filing Date:
March 14, 2023
Export Citation:
Assignee:
SHANGHAI JUNSHI BIOSCIENCES CO LTD (CN)
International Classes:
A61K39/395; A61P35/00
Domestic Patent References:
| WO2021228069A1 | 2021-11-18 |
Foreign References:
| CN110882385A | 2020-03-17 | |||
| CN108348575A | 2018-07-31 | |||
| US20170166641A1 | 2017-06-15 |
Other References:
KUDO MASATOSHI: "Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma", CANCERS, vol. 12, no. 5, 1 January 2020 (2020-01-01), pages 1089, XP093081142, DOI: 10.3390/cancers12051089
Attorney, Agent or Firm:
SHANGHAI PATENT & TRADEMARK LAW OFFICE , LLC (CN)
Download PDF: